(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
4 January 2007 (04.01.2007)

PCT

(10) International Publication Number
WO 2007/002677 A2

(51) International Patent Classification:
G01N 33/53 (2006.01) *G06F 19/00* (2006.01)

(21) International Application Number:
PCT/US2006/025003

(22) International Filing Date: 26 June 2006 (26.06.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/693,756 24 June 2005 (24.06.2005) US
11/473,826 23 June 2006 (23.06.2006) US

(71) Applicant *(for all designated States except US)*: **THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY** [US/US]; 1705 El Camino Real, Palo Alto, California 94306-1106 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **TABIBIAZAR, Raymond** [US/US]; Falk Cardiovascular Research Center, Division of Cardiovascular Medicine, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, California 94305 (US). **TSAO, Philip S.** [US/US]; 702 Meadow Lane, Los Altos, California 94022-1678 (US). **QUERTERMOUS, Thomas** [US/US]; Falk Cardiovascular Research Center, Division of Cardiovascular Medicine, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, California 94305 (US). **TURNBULL, Brit Katzen** [US/US]; 119 Quillen Court, Apt. 312, Stanford, California 94305 (US). **OLSHEN, Richard A.** [US/US]; 706 Tolman Drive, Stanford, California 94305 (US). **HYTOPOULOS, Evangelos** [GR/US]; 3724 Hillside Court, San Mateo, California 94403 (US).

(74) Agent: **SHERWOOD, Pamela J.**; BOZICEVIC, FIELD & FRANCIS LLP, 1900 University Avenue, Suite 200, East Palo Alto, California 94303 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) **Title:** METHODS AND COMPOSITIONS FOR DIAGNOSIS AND MONITORING OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE

(57) **Abstract:** The present invention identifies circulating proteins that are differentially expressed in atherosclerosis. Circulating levels of these proteins, particularly as a panel of proteins, can discriminate patients with acute myocardial infarction from those with stable exertional angina and from those with no history of atherosclerotic cardiovascular disease. Such levels can also predict cardiovascular events, determine the effectiveness of therapy, stage disease, and the like. For example, these markers are useful as surrogate biomarkers of clinical events needed for development of vascular specific pharmaceutical agents.

WO 2007/002677 A2